287 related articles for article (PubMed ID: 31795143)
1. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
Kannan S; Partridge AW; Lane DP; Verma CS
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
[TBL] [Abstract][Full Text] [Related]
2. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
[TBL] [Abstract][Full Text] [Related]
5. The facile and visualizable identification of broad-spectrum inhibitors of MDM2/p53 using co-expressed protein complexes.
Yang Y; Dong Z; Hu H; Peng J; Sheng Y; Tong Y; Yuan S; Li Z; Yang J; Wells T; Qu Y; Farrell NP; Liu Y
Analyst; 2019 Jun; 144(12):3773-3781. PubMed ID: 31089613
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Structural Determinant for Selective Targeting of HDMX.
Ben-Nun Y; Seo HS; Harvey EP; Hauseman ZJ; Wales TE; Newman CE; Cathcart AM; Engen JR; Dhe-Paganon S; Walensky LD
Structure; 2020 Jul; 28(7):847-857.e5. PubMed ID: 32359398
[TBL] [Abstract][Full Text] [Related]
7. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
8. Structure of the stapled p53 peptide bound to Mdm2.
Baek S; Kutchukian PS; Verdine GL; Huber R; Holak TA; Lee KW; Popowicz GM
J Am Chem Soc; 2012 Jan; 134(1):103-6. PubMed ID: 22148351
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
10. Effect of linker on the binding free energy of stapled p53/HDM2 complex.
Im H; Ham S
PLoS One; 2020; 15(4):e0232613. PubMed ID: 32353067
[TBL] [Abstract][Full Text] [Related]
11. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
12. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
13. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300.
Dornan D; Hupp TR
EMBO Rep; 2001 Feb; 2(2):139-44. PubMed ID: 11258706
[TBL] [Abstract][Full Text] [Related]
15. Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.
Ferreon JC; Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6591-6. PubMed ID: 19357310
[TBL] [Abstract][Full Text] [Related]
16. A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2.
ElSawy KM; Sim A; Lane DP; Verma CS; Caves LS
Cell Cycle; 2015; 14(2):179-88. PubMed ID: 25584963
[TBL] [Abstract][Full Text] [Related]
17. Acidic domain is indispensable for MDM2 to negatively regulate the acetylation of p53.
Wang Q; Yang Y; Wang L; Zhang PZ; Yu L
Biochem Biophys Res Commun; 2008 Sep; 374(3):437-41. PubMed ID: 18638452
[TBL] [Abstract][Full Text] [Related]
18. Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.
ElSawy KM; Lane DP; Verma CS; Caves LS
J Phys Chem B; 2016 Jan; 120(2):320-8. PubMed ID: 26701330
[TBL] [Abstract][Full Text] [Related]
19. Probing the origin of structural stability of single and double stapled p53 peptide analogs bound to MDM2.
Guo Z; Streu K; Krilov G; Mohanty U
Chem Biol Drug Des; 2014 Jun; 83(6):631-42. PubMed ID: 24418072
[TBL] [Abstract][Full Text] [Related]
20. α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
Sang P; Shi Y; Lu J; Chen L; Yang L; Borcherds W; Abdulkadir S; Li Q; Daughdrill G; Chen J; Cai J
J Med Chem; 2020 Feb; 63(3):975-986. PubMed ID: 31971801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
